EQS-News: Semperit AG Holding
/ Key word(s): Disposal/Strategic Company Decision
Semperit successfully completes sale of medical business and focuses on growth in industrial core business
Vienna, 31 August 2023 – The Semperit Group has successfully completed the sale of its medical business to the Southeast Asian glove manufacturer HARPS GLOBAL PTE. LTD. After receiving all regulatory approvals, the closing took place as planned today, 31 August 2023, in Vienna. The purchase price for the entire medical business agreed upon signing the contract in December 2022 amounted to EUR 115 million (cash and debt free) and was subject to usual price adjustment mechanisms; the final purchase price will be determined in each case retrospectively based on the interim balance sheet as of the closing date. “With the divestment of the medical business, we have implemented our transformation into an industrial rubber resp. elastomer specialist and will fully focus on the further development and expansion of our leading position in the core business for industrial polymer products in the future. This is where we see the greatest long-term potential for Semperit. An important growth step has already been taken with the acquisition of the Rico Group,” says Semperit CEO Karl Haider. “At the same time, we have found a responsible owner for the medical division in HARPS, which specialises in the glove business and thus expands its product portfolio and sales markets.” With the closing, the Semperit Group has disposed of the production of examination gloves and porcelain dip mouldings for the manufacture of gloves in Malaysia, as well as the global sales and distribution units, in line with its strategy. This does not include the production of surgical gloves in Wimpassing, Austria, and their packaging in Sopron, Hungary, which will continue contract manufacturing for HARPS for several years. Payment of additional dividend With the sale of the medical business, all conditions precedent for the entitlement to and payment of the additional dividend in the amount of EUR 3.00 per share for the 2022 financial year have been fully met. The payment to shareholders will be made on 14 September 2023. As of 11 September 2023, the shares of Semperit AG Holding will be traded ex additional dividend. The record date is 12 September 2023.
Contact:
www.linkedin.com/company/semperit-ag
About Semperit
31.08.2023 CET/CEST This Corporate News was distributed by EQS Group AG. www.eqs.com |
Language: | English |
Company: | Semperit AG Holding |
Am Belvedere 10 | |
1100 Wien | |
Austria | |
Phone: | +43 1 79 777-310 |
Fax: | +43 1 79 777-602 |
E-mail: | judit.helenyi@semperitgroup.com |
Internet: | www.semperitgroup.com |
ISIN: | AT0000785555 |
Listed: | Vienna Stock Exchange (Official Market) |
EQS News ID: | 1715995 |
End of News | EQS News Service |
|
1715995 31.08.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.